bluuebunny/crossref_metadata_2025_split huggingface dataset:
EEG Reveals Alterations in Motor Imagery in People With Amnestic Mild Cognitive Impairment
Authors: Zhen Yanfen , Gao Lijuan , Chen Jiu , Gu Lihua , Shu Hao , Wang Zan , Liu Duan , Zhang Zhijun 
Published: May 2023

Abstract

Objectives
Motor imagery has been used to investigate the cognitive mechanism of motor control. Although behavioral and electrophysiological changes in motor imagery in people with amnestic mild cognitive impairment (aMCI) have been reported, deficits in different types of imagery remain unclear. To explore this question, we used electroencephalography (EEG) to study neural correlates of visual imagery (VI) and kinesthetic imagery (KI) and their relationship to cognitive function in people with aMCI.

Methods
A hand laterality judgment task was used to induce implicit motor imagery in 29 people with aMCI and 40 healthy controls during EEG recording. Mass univariate and multivariate EEG analysis was applied to explore group differences in a data-driven manner.

Results
Modulation of stimuli orientation to event-related potential (ERP) amplitudes differed significantly between groups at 2 clusters located in the posterior–parietal and frontal areas. Multivariate decoding revealed sufficient representation of VI-related orientation features in both groups. Relative to healthy controls, the aMCI group lacked accurate representation of KI-related biomechanical features, suggesting deficits in automatic activation of KI strategy. Electrophysiological correlates were associated with episodic memory, visuospatial function, and executive function. Higher decoding accuracy of biomechanical features predicted better executive function via longer response time in the imagery task in the aMCI group.

Discussion
These findings reveal electrophysiological correlates related to motor imagery deficits in aMCI, including local ERP amplitudes and large-scale activity patterns. Alterations in EEG activity are related to cognitive function in multiple domains, including episodic memory, suggesting the potential of these EEG indices as biomarkers of cognitive impairment.
Dwork Crystals III: From Excellent Frobenius Lifts Towards Supercongruences
Authors: Beukers Frits , Vlasenko Masha 
Published: May 2023

Abstract
This paper is a continuation of our Dwork crystals series. Here we exploit the Cartier operation to prove supercongruences for expansion coefficients of rational functions. In the process, it appears that excellent Frobenius lifts are a driving force behind supercongruences. Originally introduced by Dwork, these excellent lifts have occurred rather infrequently in the literature, and only in the context of families of elliptic curves and abelian varieties. In the final sections of this paper, we present a list of examples that occur in the case of families of Calabi–Yau varieties.
From Delaunay triangulation to topological data analysis: generation of more realistic synthetic power grid networks
Authors: Dey Asim K , Young Stephen J , Gel Yulia R 
Published: May 2023

Abstract
Assessing novel methods for increasing power system resilience against cyber-physical hazards requires real power grid data or high-quality synthetic data. However, for security reasons, even basic connection information for real power grid data are not publicly available. We develop a randomised model for generating realistic synthetic power networks based on the Delaunay triangulation and demonstrate that it captures important features of real power networks. To validate our model, we introduce a new metric for network similarity based on topological data analysis. We demonstrate the utility of our approach in application to IEEE test cases and European power networks. We identify the model parameters for two IEEE test cases and two European power grid networks and compare the properties of the generated networks with their corresponding benchmark networks.
Estimating a brain network predictive of stress and genotype with supervised autoencoders
Authors: Talbot Austin , Dunson David , Dzirasa Kafui , Carlson David 
Published: May 2023

AbstractTargeted brain stimulation has the potential to treat mental illnesses. We develop an approach to help design protocols by identifying relevant multi-region electrical dynamics. Our approach models these dynamics as a superposition of latent networks, where the latent variables predict a relevant outcome. We use supervised autoencoders (SAEs) to improve predictive performance in this context, describe the conditions where SAEs improve predictions, and provide modelling constraints to ensure biological relevance. We experimentally validate our approach by finding a network associated with stress that aligns with a previous stimulation protocol and characterizing a genotype associated with bipolar disorder.
(020) Implementing a Virtual Mindfulness-based Group Therapy to Improve Male Sexual Dysfunction
Authors: Campbell J , Pignanelli M , Deroches D , Macdonald J 
Published: May 2023

Abstract

Introduction
Erectile dysfunction (ED) is almost always multi-factorial. Simultaneous performance anxiety and psychogenic inhibition can impair erectile function even when underlying organic aetiologies are present. Sex therapy should be considered first-line treatment for ED. Mindfulness is a technique to focus on being aware of what you're sensing and feeling in the moment, without interpretation or judgment. Mindfulness-based therapy programs have been successful at improving female sexual dysfunction and prostate cancer survivors quality of life (QOL).

Objective
To design and evaluate the feasibility of a virtual, mindfulness-based group therapy (vMBGT) program for patients experiencing mild-to-moderate ED. We secondarily assess relationship satisfaction, QOL, and changes in erectile function after intervention.

Methods
A mixed-methods approach was taken for this feasibility pilot study. A total of 18 participants (mean age: 42; range 22-69 years) with ED were recruited to participate in a 4-week virtual mindfulness-based group therapy program. Three groups were led by trained facilitators on a weekly basis via Webex platform and ran 1.5-2 hours in length, followed by daily home-practice and sex education between sessions. Participants completed questionnaires (International Index of Erectile Functioning, Erection hardness scale, Relationship Assessment Scale, Five Facets of Mindfulness Questionnaire) as a baseline and 3 months after treatment. Qualitative exit interviews and program feedback was requested from all participants.

Results
The dropout rate for this study was 11%. Two of the eighteen men missed 2 of the 4 sessions; one participant dropped out and one had unanticipated work commitments. There was a statistically significant improvement in the mean IIEF scores from baseline 41 to 49 after vMBGT intervention (p &lt; 0.05). There was a clinically significant improvement in SHIM score by 4 points. There was an improvement in EHS at 3 months compared to baseline (p=0.08) Overall, feedback was positive, and all participants responded that they would recommend this program to others. Some participants felt that the material could be lengthened to 6 weeks and/or that an in-person setting would have been more interactive, whereas others appreciate the convenience and comfort of the virtual platform.

Conclusions
This is the first published vMGBT program for patients experiencing mild to moderate ED. This program is feasible, the content was well received, and patients had improvement in their erectile function and QOL. Our pilot study has provoked a change to the treatments we can offer patients with ED and we have modified the program based on feedback. Further studies are needed to compare this to medical management and other psychotherapy interventions.

Disclosure
No
(045) The Importance of Fertility Preservation in the Transgender Population
Authors: Parikh N , Cannon G , Chattha A , Gargollo P , Orwig K , Mcclendon B , Walker D , Granberg C 
Published: May 2023

Abstract

Introduction
The transgender population has long been marginalized by society. Societal stigmata, fear to seek care, and dearth of provider knowledge regarding transgender health issues has caused disparities to widen.

Objective
The purpose of this case study is to call to attention the often-overlooked aspect of pediatric transgender care: the importance of fertility preservation prior to instituting gender-affirming therapy.

Methods
Twenty-one genetically XY females, followed by their multidisciplinary transgender care teams, were interested in starting hormone therapy due to impending onset and/or progression of puberty. Fortunately for these patients, their physicians were aware of fertility struggles after undergoing hormone therapy.

Results
Sperm cryopreservation via open gonadal biopsy, testicular tissue cryopreservation (TTC), and semen sample (when age/maturity-appropriate) were discussed. Though requiring surgery, biopsy/TTC relieves patients of the psychological impact of semen sample production. With IRB approval, 20 patients (median age 12 years, range 10-16 years) underwent TTC (Figure 1). One patient (age 16 years) opted for semen sample. All patients had success with spermatogonial stem cells cryopreserved for future patient use.

Conclusions
Gender affirming procedures and hormone therapy affect the long-term reproductive potential of transgender individuals. While cost concerns and insurance coverage regarding oncofertility is a prominent area of discussion, the transgender community is often excluded. With more individuals beginning medical and surgical therapy at a younger age, fertility preservation discussions are essential but often overlooked, depriving these individuals the joy of becoming a biological parent. As health care providers, addressing psychological, emotional, physical, and spiritual needs of patients is crucial, and fertility is a key aspect of this care. TTC can be safely done in pediatric populations, though research is necessary to expand beyond current experimental stage of tissue-development.

Disclosure
No
(050) Low Prolactin Level Identifies Hypoactive Sexual Desire Disorder Women With a Reduced Inhibition Profile
Authors: Maseroli E , Verde N , Cipriani S , Rastrelli G , Scairati R , Minnetti M , Maggi M , Vignozzi L 
Published: May 2023

Abstract

Introduction
Data on the role of prolactin (PRL) in the physiologic range in the female sexual response are scanty.

Objective
To investigate the association between PRL and sexual function as assessed by the Female Sexual Function Index (FSFI). We explored the presence of a cut-off level of PRL able to identify Hypoactive Sexual Desire Disorder (HSDD).

Methods
N=264 pre- and post-menopausal women consulting for FSD and sexually active were included in this observational, retrospective study. A clinical, biochemical and psychosexual evaluation was performed. Main Outcome measures: FSFI, Female Sexual Distress Scale-Revised, Middlesex Hospital Questionnaire and Sexual excitation/sexual inhibition scale (SIS/SES). HSDD was diagnosed through a clinical interview.

Results
In a multivariate model, PRL showed a significant, positive correlation with FSFI Desire (p=0.009) and Satisfaction (p=0.011). Women with PRL in the V quintile (14.58-24.59 μg/L) reported significantly higher FSFI Desire scores than those with PRL in the I quintile (5.12-6.53 μg/L). Women with HSDD presented a significantly lower PRL level than those without (p=0.032). A ROC curve analysis for PRL showed an accuracy of 0.610+-0.044 (p=0.014) in predicting HSDD. With a threshold of 9.83 μg/L, sensitivity and specificity for HSDD were 63% and 56%, respectively. Subjects with PRL =9.83 μg/L. The difference in SIS1 score was independent of cortisol.

Conclusions
Among FSD women with normo-PRL levels, those with the lowest levels demonstrated a poorer sexual desire than those with the highest levels. PRL &lt;9.83 μg/L could predict HSDD and a lower sexual inhibitory trait.

Disclosure
Any of the authors act as a consultant, employee or shareholder of an industry for: LV received scientific research grants, advisory board attendance and speaker honoraria from Therascience, Theramex, Bayer Schering Pharma, Intercept, Lipocine, Ibsa.
(053) The Prevalence of Low Sexual Desire Among Premenopausal Women and Their Wish for Drug Treatment
Authors: Reisman Y , Varod S 
Published: May 2023

Abstract

Introduction
Low female sexual desire (HSDD) is one of the most common sexual complaints in women. As a result, many women suffer from sexual dissatisfaction and related distress, which often negatively interferes with their quality of life. Little is known about the underlying biological mechanism of low desire, but it is conceivable that sexual functions are the result of an interaction between biological, psychological, and relational factors, for which neurological and hormonal central and peripheral processes are involved. Women's sexual desires naturally fluctuate over the years and commonly coincide with the beginning or end of a relationship, health status, medication use, and/or major life events. The treatment approach for females with low sexual desire is aimed at the many causes behind this condition. Recommendations may include sex education, counseling, and sometimes medication and hormone therapy mainly for women who go through menopause or post-menopause. So far no medical therapy for HSDD is available in Europe. While some women movements, such as “right to desire” wish to support the development of drugs for HSDD and reduce the distress associated with HSDD, others are against what they call “the pathologizing of variation in the population” and drug developments.

Objective
The aim of this survey was to find the prevalence of HSDD among young, premenopausal, social media active women and their willingness to receive medical therapy.

Methods
A social media survey has been conducted among women between 18 and 50 years old who are regularly using social media apps, in Israel. A country with a mix of cultures, religions, and personal social backgrounds. Women were asked about their sexual desire, current experience with a reduction of their desire for more than 6 months, and the presence of distress. Women who suffer from low desire have been asked about their willingness to receive medical treatment for this condition.

Results
4079 women observed the survey but only 1493 (36.6%) answered the questions. 42% (624) stated that they suffer from a decline in desire for a period longer than 6 months, while 49% (727) said they did not suffer from a decline in sexual desire. 9% (142) of the women answered that they didn’t know. On the question: “would you be interested in drug treatment ‘that ’ was asked only to the women who reported a decline in sexual desire, 22% (138) were interested in drug treatment, 40% (249) were not interested in drug treatment, 12% (75)said they don’t know and 26% (162) stated that their wiliness to use a drug for HSDD depended on the risk and benefits.

Conclusions
HSDD is prevalent even among premenopausal women in a multicultural country. Despite the multifactorial factors involved in the etiology of HSDD, almost half of the women have an interest in using a safe medication for HSDD.

Disclosure
Any of the authors act as a consultant, employee or shareholder of an industry for: Freya, Besins, Ohhmed.
(059) Surrogate Treatment- A Case Study of 151 male clients and surrogacy coaching.
Authors: Shyam D A , Kaye D S 
Published: May 2023

Abstract

Introduction
Surrogate Treatment: A retrospective case-based study of 151 male clients obtained from the archives of three professional surrogate coaches. Surrogate Treatment is also known as Sex Surrogate therapy/Partner Therapy was created in the 1960s by the Medical and Sex Research team of Dr. William Masters and Virginia Johnson. It is significant in aiding clients to improve their social and sexual problems, as well as remedy diagnosed disorders. This research identifies social and sexual barriers which inhibit clients from experiencing healthy relationships and the feeling of sexual well-being. To overcome these barriers, the surrogate treatment enables the client to experience medical, psychological, social, and sexual healing. It is a treatment that combines the integration of physical and mental health. This research defines and examines the surrogate treatment, surrogate coaches, and the clients that participate in this treatment. It also demonstrates the medical and mental health role in Masters & Johnson’s “Triadic model”. The triad consists of body practitioners, therapists, and the patient/client. Inside this examination will include a description of sensate focus body-focused techniques that are the center of M&J’s surrogate treatment.

Objective
The purpose of this study is two-fold: 1) to evaluate the degree of success in the correction of the client's stated physical and mental problem and 2) the clinical and mental/sexual resolution of their diagnosed social and/or sexual disorder.

Methods
The result of this analysis is presented quantitatively in tables and qualitatively reported in a narrative-expository form. A number of themes emerged based upon the verbal interviews, with the three professional surrogate coaches as well as the data recorded during the medical and psychological clients' history-taking process. These are representational descriptions of the stated problem as self-defined by the clients and/or the referring physician. These themes are categorized as follows: 1) fear of women, 2) lack of social and sexual confidence and experience, 3) shyness and anxiety around social and sexual situations, 4) inability to develop intimate relationships, 5) lack of social and sexual education, 6) inability to perform sexually, 7) emotional and mental pain of childhood abuse and 8) lack of sexual desire.

Results
The implications of this study are that socioeconomics, education, age, religious backgrounds or sexual practices do not limit the success of the sensate focus and socialization techniques in surrogate treatment.

Conclusions
The statistical data demonstrates that clients who complete sensate focus exercises, as well as other body-focused or somatic practices also achieve resolution of their diagnosed disorder.

Disclosure
No
(060) Chronology of Endogenous Testosterone Recovery Following Androgen Deprivation Therapy Cessation – Results From a Prospective Analysis
Authors: Nascimento B C G , Pedrenho Neto R , Zandona P , De Bessa J , Bastos D , Cordeiro M , Coelho R , Nahas W , Hallak J , Mulhall J , Gomes C 
Published: May 2023

Abstract

Introduction
Testosterone (T) recovery after androgen deprivation therapy (ADT) is reported in the literature from 7 to 96%, with data mainly from retrospective studies using variable definitions for this event. Age, Diabetes and ADT duration may affect the timing and completeness of recovery

Objective
Prospectively evaluate the chronology of T recovery following ADT cessation

Methods
This is a secondary analysis of a prospective oncological study designed to evaluate the impact of neoadjuvant use of ADT in combination with abiraterone acetate and prednisone with or without apalutamide in patients with high-risk prostate cancer. Both regimens were administered for 3 months before radical prostatectomy (RP). Early morning Total T (TT) levels were collected (immunoassay) at baseline and periodically (3, 6 and 12 months) after ADT cessation. 3 outcomes for T recovery were evaluated: return to non-castrate level (TT &gt;50 ng/dL), to normal T (TT ≥ 300 ng/dL) and back to baseline level (BTB –TT≥ baseline level). We performed a time-to-event analysis and reported the cumulative incidence of each outcome. Multivariable analysis was conducted to investigate predictors of recovery

Results
In this preliminary report, from 64 initially enrolled patients, 1 year follow-up T data from 50 pts were available. Mean age was 64.6 ± 5.89 years, 28% had type 2 diabetes (DM) and 61% hypertension (HTN). Mean TT levels were 450 ± 170ng/dl at baseline, 112. 7± 96.9 at 3m, 208.5 ±197 at 6m, 337.7 ± 170 at 9m and 378.2 ± 166 at 12 m. Figure 1 shows the cumulative incidence of each outcome according to time. Median time to achieve T&gt;50 was 5 m, to achieve T&gt;300 was 9.1m and BTB 13.13 m. At 1 year, 98% had returned back from castrate-level, 76% had TT normalized and 42% had return BTB. In a multivariable analysis including DM, HTN, age and baseline T, only baseline T was associated with a greater chance of recovery, with 88.5% of those with baseline T &gt; 450 ng/dl achieving normal T at 1y vs 46.9% for patients with baseline T &lt; 450 ng/dl (HR: 3.56, p&lt; 0.001)

Conclusions
In this prospective analysis of a population exposed to neoadjuvant short-term ADT, T recovery rates after 1 year showed that the vast majority (98%) had returned back from castrate level (median time 5m), about 2/3 recovered back to normal levels (median time 9,1m) and less than half returned to BTB level. Baseline TT was the only predictor of T recovery

Disclosure
Yes, this is sponsored by industry/sponsor: Source of Funding: Janssen-Cilag Farmacêutica Ltda

Clarification
Industry funding only - investigator initiated and executed study
(066) Low Serum Testosterone and Mortality After Solid Organ Transplantation: A Multi-institutional Analysis of the TriNetX Research Network
Authors: Omil-Lima D , Perez J A , Sellke N , Patel A , Thompson A , Khera M , Chavin K , Thirumavalavan N 
Published: May 2023

Abstract

Introduction
Low serum testosterone has previously been suggested as a predisposing factor contributing to mortality after solid organ transplant. Previous studies on this topic stem from single-center retrospective series.

Objective
To determine the impact of low serum testosterone as a risk factor for mortality after solid organ transplantation using TriNetX, a large de-identified, multi-institutional database.

Methods
Data source, Patient Selection, and Outcomes We compiled all clinical data from the TriNetX research network, a health research network (with waiver from Western IRB) that provides de-identified clinical information from 58 health care organizations, and over 80 million patients located within the United States. We selected male patients (age ≥ 18) with a history of lung, kidney, liver, heart, or pancreas transplant. Cases were included if serum testosterone was drawn within one year before transplant. We excluded all patients previously on testosterone therapy. We categorized patients into two groups, based on testosterone levels. We defined patients as having low testosterone (Low T) by the following criteria: total testosterone &lt; 300 (ng/Dl), or a diagnosis of hypogonadism (ICD-10: E29.1). For all patients, clinical characteristics/demographics including comorbidities, laboratory findings, and medication use were compared using descriptive statistics. Our outcomes of interest were mortality at 1-year, 3-year, or at any time. Statistical analyses We evaluated differences in baseline characteristics between testosterone levels (Normal T, or Low T), using chi-square or Fisher’s exact test for categorical data and an independent t-test for continuous data. To address potential confounders that could bias our results, we used a propensity score weighted regression matched on age, race/ethnicity, comorbid conditions, multiple transplant status, and immunosuppressant use. A Cox regression model was used to determine the probability of mortality. All analyses were performed using R version 4.0.4.

Results
A total of 1,762 men were identified with solid organ transplants. Of these, 792 men met criteria for low testosterone (Table 1). Low testosterone correlated with higher rates of mortality at 1 year, 3 years, and all-time mortality (Figure 1).

Conclusions
Low testosterone at the time of transplant is correlated with mortality up to 3 years after organ transplantation. Future work will focus on individual organ transplants and whether modifying this risk factor with testosterone therapy changes outcomes.

Disclosure
No